Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Remon

Showing results (11-20 of 184) with videos related to

Pageof 19
Sort By:
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?Jessica Menis, Jordi Remon
ESMO Open|November 15, 2018
Precision oncology: separating the wheat from the chaffJordi Remon, Rodrigo Dienstmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2026
Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Current Opinion in Oncology|January 13, 2016
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerJordi Remon, Nathalie Chaput, David Planchard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2023
Speeding up Antibody-Drug Conjugate Development in Pretreated <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerLizza E L Hendriks, Jordi Remon
Cancer Management and Research|June 20, 2019
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to dateJordi Remon, Laura Esteller, Álvaro Taus
European Respiratory Review : an Official Journal of the European Respiratory Society|October 7, 2021
The efficacy of immune checkpoint inhibitors in thoracic malignanciesJordi Remon, Francesco Facchinetti, Benjamin Besse
The European Respiratory Journal|May 2, 2016
The 5000% case: a glimpse into the financial issue of lung cancer treatmentJordi Remon, Julia Bonastre, Benjamin Besse
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L Hendriks
Translational Lung Cancer Research|May 13, 2024
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinibBoris Duchemann, Emmanuelle Fabre, Jordi Remon
Pageof 19

Showing results (11-20 of 184) with videos related to

Sort By:
Pageof 19
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?Jessica Menis, Jordi Remon
ESMO Open|November 15, 2018
Precision oncology: separating the wheat from the chaffJordi Remon, Rodrigo Dienstmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2026
Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Current Opinion in Oncology|January 13, 2016
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerJordi Remon, Nathalie Chaput, David Planchard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2023
Speeding up Antibody-Drug Conjugate Development in Pretreated <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerLizza E L Hendriks, Jordi Remon
Cancer Management and Research|June 20, 2019
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to dateJordi Remon, Laura Esteller, Álvaro Taus
European Respiratory Review : an Official Journal of the European Respiratory Society|October 7, 2021
The efficacy of immune checkpoint inhibitors in thoracic malignanciesJordi Remon, Francesco Facchinetti, Benjamin Besse
The European Respiratory Journal|May 2, 2016
The 5000% case: a glimpse into the financial issue of lung cancer treatmentJordi Remon, Julia Bonastre, Benjamin Besse
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L Hendriks
Translational Lung Cancer Research|May 13, 2024
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinibBoris Duchemann, Emmanuelle Fabre, Jordi Remon
Pageof 19